Phase 2 N=23 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=80 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Scleroderma · Raynaud's Syndrome
Primary: Change in Digital Blood Flow From Pre- to Post-injection. — -36.19; -6.10 Blood flow, measured in LDI flux units,
Phase 2 N=233 The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
Pelvic Inflammatory Disease
Primary: Clearance of Anaerobic Organisms From the Endometrium — 14; 18; 7; 1 participants — p=0.046
Phase 2 N=23 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Liver Cirrhosis · Hepatic Cirrhosis · Portal Hypertension
Primary: Hepatic Venous Pressure Gradient (HVPG) — 15.2; 8.05; 20.62; 14.1 mmHg — p=0.257
N/A N=491 Foley OR MisO for the Management of Induction
Delivery; Prolonged
Primary: Time to Delivery — 13.1; 17.6; 17.7; 14.5 Hours
Phase 3 N=450 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
B-Cell Chronic Lymphocytic Leukemia
Primary: Kaplan-Meier Estimate of Progression Free Survival (PFS) — 30.8; 23.0 months — p=0.323
Phase 4 N=55 Effect IV Ibuprofen and Inflammatory Responses
Gallbladder Disease
Primary: Stress Response Inflammation Markers :Cortisol and C Reactive Protein (CRP) — 173.6; 289.5; 17; 17 pg/mL
N/A N=273 Treatment Outcomes for Ankle Arthritis
Osteoarthritis
Primary: Musculoskeletal Functional Assessment (MFA) — -12.5; -15.0 units on a scale
Phase 4 N=37 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Hemophilia A
Primary: Percentage of Participants With Clinically Significant Factor VIII Inhibitor Development — 0.00; 0.00 percentage of participants
Phase 2 N=7 A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
Autosomal Dominant Hypocalcemia (ADH)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 1 participants
N/A N=170 Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste
Dysgeusia
Primary: Association Between Gustin Gene Polymorphism and PROP Sensitivity — 85.19; 50.99; 25.00; 14.81 percentage of participants — p=<0.01
Phase 3 N=130 Vitamin D in Vulnerable Adults (VIVA-VA)
Frail Elderly · Vitamin d Deficiency
Primary: Change in Short Physical Performance Battery Test Score — 7.3; 7.0 units on a scale
Phase 2 N=18 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Indolent Non-Hodgkin's Lymphoma · Follicular Lymphoma · Small Lymphocytic Lymphoma
Primary: Overall Safety of Idelalisib — 88.9; 27.8; 55.6; 83.3 percentage of participants
Phase 2 N=21 Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
Mouth Neoplasms
Primary: Change in IL-2 Levels — 1.8; 4.0; 7.9; 2.1 pg/100 gm protein — p=<0.05
Phase 3 N=69 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
Diabetes Mellitus, Type 2
Primary: Overview of Adverse Event Profile (Treatment Emergent Adverse Events) of the One-Step and Two-Step Titration Arms Assessed Through Adverse Events Collection and Vital…